All In Biotech

Drug Trial Radar · NCT07168226

Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101

A Multi-center, Randomized, Phase 2 Clinical Trial to Exploratively Evaluate the Efficacy and Safety of ASCA101 for the Treatment of Cachexia in Patients With Solid Tumor

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

May 8, 2026

Primary completion

Apr 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
MetaFinesIndustry
Sponsor type
Industry
First posted
Sep 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of ASCA101 for the treatment of Cachexia in solid tumor patients. The main questions it aims to answer are: Can the efficacy of ASCA101 in improving cachexia be evaluated based on changes in body weight measured by InBody after 12 weeks (3 cycles) of weekly administration, compared to baseline, for each dose group? Do participants experience adverse events during administration of ASCA101 and/or within 4 weeks after the end of administration? This clinical trial comprises two parts. \[Study 1. Active-Controlled, Open-Label Study\] Participants who provide written informed consent will undergo screening procedures. Those who meet all inclusion criteria and none of the exclusion criteria will be eligible for enrollment and will be randomized to receive either ASCA101 (at one of two dose levels: 24.32 or 32.43 mg/kg) or an active control. Participants will receive the investigational product over 3 cycles (12 weeks). Each cycle consists of 28 days. Subjects in the ASCA101 group will receive the investigational drug twice weekly for a total of 8 doses per cycle. Participants in the active control group (megace F suspension) will receive the drug orally once daily. \[Study 2. Placebo-Controlled, Double-Blind Study\] Participants who provide written informed consent will undergo screening procedures. Those who meet all inclusion criteria and none of the exclusion criteria will be eligible for enrollment and will be randomized to receive either ASCA101 (at one of two dose levels: 24.32 or 32.43 mg/kg) or placebo. Participants will receive the investigational product over 3 cycles (12 weeks). Each cycle consists of 28 days. Subjects in the ASCA101 group will receive the investigational drug twice weekly for a total of 8 doses per cycle. Participants in the placebo group will receive placebo in the same manner as the ASCA101 group.

Conditions

  • Cachexia; Cancer

Interventions

  • Active ComparatorDrug

    Megace F suspension 625mg(5mL), intake daily for 12weeks

  • ASCA101 24.32mg/kgDrug

    ASCA101 Inj. 24.32mg/kg, twice a week for 12 weeks

  • ASCA101 32.43mg/kgDrug

    ASCA101 Inj. 32.43mg/kg, twice a week for 12 weeks

  • PlaceboDrug

    0.9% normal saline injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in body weight at the end of cycle 3 compared to baselineTime frame: At Screening, baseline(0 week), End of Cycle 1, End of Cycle 2, End of Cycle 3. (Each cycle is 28days.)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, Gangnam-gu, South Korea · Recruiting

  • National Cancer Center

    Gyeonggi-do, Goyang-si, South Korea · Recruiting

  • Chung-Ang University Gwangmyeong Hospital

    Gyeonggi-do, Gwangmyeong-si, South Korea · Recruiting

  • Seoul ST. Mary's hospital

    Seoul, Seocho-gu, South Korea · Recruiting

  • Korea University Anam Hospital

    Seoul, Seongbuk-gu, South Korea · Recruiting

  • Ajou University Hospital

    Gyeonggi-do, Suwon-si, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.